MTVA
$1.52
Market ClosedAs of Mar 17, 8:00 PM UTC
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases.
Historical Price
Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.52
Potential Upside
5%
Whystock Fair Value$1.60
Price
UndervaluedFair ValueOvervalued
Fundamentals
MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$5.04M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-168.18%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
1.69
